New ASX share everyone's ignoring is ready to skyrocket: analysts

Everyone's now fatigued with IPOs, so this might be an opportunity that's been overlooked by most investors.

| More on:
A tired healthcare or lab worker sleeps on her desk

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An ASX share that only listed a few weeks ago is being ignored by investors, even though next month's reporting season could light a fire under it.

That's according to Wilson Asset Management portfolio managers Matthew Haupt, Catriona Burns and Oscar Oberg, who reckon the pathology services provider has bright long-term prospects.

"Australian Clinical Labs Ltd (ASX: ACL) continues to benefit from record levels of testing due to the coronavirus, which have extended further given the spread of the more infectious Delta variant," they wrote in a memo to clients.

"The company has 86 accredited laboratories and services in approximately 90 public and private hospitals."

Both the WAM Capital Limited (ASX: WAM) and WAM Research Limited (ASX: WAX) listed investment companies hold shares in Australian Clinical Labs.

IPO-weary market underestimating ACL's potential

The company floated on the ASX in May with an initial public offer price of $4 a share. It has since disappointed IPO-weary investors.

The stock is trading at $3.64 around midday on Friday. 

"Australian Clinical Labs has underperformed as the market rotated away from companies perceived as coronavirus beneficiaries," read the Wilson memo.

"However, we think the market is underestimating the underlying earnings power of the business given the substantial work undertaken to drive automation of systems and processes prior to listing, which is not readily visible to investors."

The portfolio managers thought that the short-term success would allow the company to scale and expand its market share in the longer term.

The improving balance sheet would provide it with a chance to acquire earnings-accretive assets in Australia and in overseas markets like the US.

"White-labelling of lab services also presents further growth opportunities," said the memo.

"And over time, we expect superior organic growth rates and successful inorganic expansion to drive a re-rating in Australian Clinical Labs' valuation towards peers, versus its current discount of greater than 30%."

The trio said the company was a classic example of an ASX share that's "overlooked and under-researched" by investors.

"We view the upcoming reporting season as a catalyst for investors to revisit these companies."

The Melbourne-headquartered company currently has a market capitalisation of $727 million, according to the ASX. Australian Clinical Labs employs more than 3,800 staff.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »